Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWRimantadine is a derivative of amantadine (Item No. 21364) with antiviral activity.1 It inhibits recombinant influenza A matrix protein 2 (M2) expressed in X. laevis oocytes (IC50 = 10.8 µM) and recombinant hepatitis C virus (HCV) p7 protein expressed in HEK293 cells (IC50s = 0.7, 24, 1.6, and 3.0 nM for HCV genotypes 1a, 2a, 3a, and 4a, respectively).2,3 Rimantadine inhibits cytotoxicity induced by the influenza A strains A/PR/8/34 (H1N1) and A/HK/7/87 (H3N2), but not the influenza B strain B/HK/72, in MDCK cells (EC50s = 18, 0.62, and >500 µM, respectively).4 It increases the survival rate of mice infected with the influenza A strain A2/Jap/305 from 20 to 90% when administered at a dose of 24 mg/kg two hours post-infection, with the survival rate decreasing when rimantadine is administered at longer timepoints following infection.5 It also has trypanocidal activity against bloodstream forms of T. brucei in vitro (IC50 = 1.26 µg/ml).6 Formulations containing rimantadine have been used in the prophylaxis and treatment of influenza A.
WARNING This product is not for human or veterinary use.
1. Antiviral therapy: Current concepts and practices. Clin. Microbiol. Rev. 5(2), 146-182 (1992).
2. Discovery of novel dual inhibitors of the wild-
3. Patch-
4. 3-
5. Rimantadine therapy of influenza A infection in mice. Antimicrob. Agents Chemother. 1(5), 408-411 (1972).
6. The anti-